Local treatment Associated With Prognosis among Men With Metastatic Prostate Cancer: A SEER-Based Study

被引:0
|
作者
Zhou, Jiatong [1 ]
Cao, Yiqun [1 ]
Chen, Haojie [1 ]
Wu, Yanyuan [1 ]
Ding, Jie [1 ,2 ]
Qi, Jun [1 ,2 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Urol, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Urol, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China
基金
中国国家自然科学基金;
关键词
mPCa; RP; RT; OS; CSS; SURVIVAL; THERAPY; TUMOR;
D O I
10.1016/j.clgc.2023.01.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
local treatment may not effectively improve the prognosis of mPCa patients. Patients with low level PSA under-went local treatment had better OS. Compared with RT, RP could effectively improve the prognosis of mPCa patients. Introduction: In order to identify the impact of local treatment on overall survival (OS) and cancer-specific survival(CSS) in men with mPCa. Materials and methods: Men with mPCa undergoing local treatment by radical prostatectomy (RP), radiotherapy (RT) including beam radiation and brachytherapy or no local treatment identified from Surveillance, Epidemiology, and End Results (SEER) database (2010-2015). To evaluate local therapy impact on OS and CSS in relation to baseline character istics, univar iate and multivar iable Cox regression analysis was used to predict the prognos-tic value of local therapy in OS and CSS. Results: A total of 902 (25.8%) patients received local treatment and 2598 (74.2%) patients did not receive local treatment in this study. The Kaplan-Meier curves showed that there was significant difference in OS between patients underwent local treatment and patients without local treatment (P = .013) but not in CSS (P = .068). While multivariate Cox regression analysis showed that local treatment may not significantly improve OS(P = .724). In subgroup analysis, Among patients with prostate-specific antigent (PSA) < 10ng/ml, local treatment could significantly improve OS and CSS (all P < .05). Multivariate Cox regression analysis showed that local treatment could be used as an independent prognostic factor to improve OS in mPCa patients with PSA < 10ng/ml (P = .031). Another multivariate Cox regression analysis demonstrated that patients with mPCa undergoing RP had better OS and CSS (all P < .05). Conclusions: Our results showed that local salvage therapy did not seem to be an independent prognostic factor in all mPCa patients, but we found that local therapy can show a better prognosis in patients with lower PSA levels. Compared with RT, patients who had experienced RP may have better prognosis. We still need prospective research to further study the application value of local treatment in mPCa patients.
引用
收藏
页码:E204 / E215
页数:12
相关论文
共 50 条
  • [31] Prognostic significance of molecular subtype, metastatic site and primary tumor surgery for survival in primary metastatic breast cancer A SEER-based study
    Li, Yang
    Wang, Shuaibing
    Yang, Wenbo
    Liu, Hong
    MEDICINE, 2021, 100 (27)
  • [32] Prognostic factors impacting survival rates of hypopharyngeal cancer with nomogram prediction: a SEER-based study
    Tawfik, Gehad Mohamed
    Vuong, Nguyen Lam
    Zayan, Ahmad Helmy
    Abdelaal, Abdelaziz
    Tieu, Thuan Minh
    Sang, To Kim
    Ebied, Amr
    Shafik, Amr G.
    Huy, Nguyen Tien
    EGYPTIAN JOURNAL OF OTOLARYNGOLOGY, 2022, 38 (01):
  • [33] Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry
    Borno, Hala T.
    Cowan, Janet E.
    Zhao, Shoujun
    Broering, Jeanette M.
    Carroll, Peter R.
    Ryan, Charles J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (10) : 793.e1 - 793.e11
  • [34] Metastatic hormone sensitive prostate cancer: local treatment strategies
    Walz, Jochen
    Pignot, Geraldine
    Fakhfakh, Sami
    Campagna, Jennifer
    Guerin, Mathilde
    Vicier, Cecile
    Brunelle, Serge
    Salem, Naji
    Gravis, Gwenaelle
    WORLD JOURNAL OF UROLOGY, 2021, 39 (02) : 327 - 337
  • [35] Disparities in Diagnosis, Treatment Access, and Time to Treatment Among Hispanic Men With Metastatic Prostate Cancer
    Hougen, Helen Y.
    Swami, Nishwant
    Dee, Edward Christopher
    Alshalalfa, Mohammed
    Meiyappan, Karthik
    Florez, Narjust
    Penedo, Frank J.
    Nguyen, Paul L.
    Punnen, Sanoj
    Mahal, Brandon A.
    JCO ONCOLOGY PRACTICE, 2023, 19 (08) : 645 - +
  • [36] Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study)
    Buelens, Sarah
    Poelaert, Filip
    Claeys, Tom
    De Bleser, Elise
    Dhondt, Bert
    Verla, Wesley
    Ost, Piet
    Rappe, Bernard
    De Troyer, Bart
    Verbaeys, Caroline
    Kimpe, Bart
    Billiet, Ignace
    Plancke, Hendrik
    Fransis, Karen
    Willemen, Patrick
    Ameye, Filip
    Decaestecker, Karel
    Lumen, Nicolaas
    BJU INTERNATIONAL, 2022, 129 (06) : 699 - 707
  • [37] A nomogram for predicting prognosis for young cervical neuroendocrine carcinoma: A SEER-based study and external validation
    Xie, Ning
    Yu, Haijuan
    Lin, Jie
    Deng, Sufang
    Liu, Linying
    Sun, Yang
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [38] Nomogram predicting overall prognosis for invasive micropapillary carcinoma of the breast: a SEER-based population study
    Liu, Jianpeng
    Xi, Wei
    Zhou, Jiahao
    Gao, Wei
    Wu, Qiaolin
    BMJ OPEN, 2023, 13 (08):
  • [39] Impact of environmental temperature on the survival outcomes of breast cancer: A SEER-based study
    Gupta, Ashish
    Roy, Arya Mariam
    Gupta, Kush
    Attwood, Kristopher
    Gandhi, Asha
    Edge, Stephen
    Takabe, Kazuaki
    Repasky, Elizabeth
    Yao, Song
    Gandhi, Shipra
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 207 (02) : 383 - 392
  • [40] Prognostic significance of surgery and radiotherapy in elderly patients with localized prostate cancer: establishing and time-based external validation a nomogram from SEER-based study
    Chenghao Zhanghuang
    Jianjun Zhu
    Ye Li
    Jinkui Wang
    Jing Ma
    Li Li
    Zhigang Yao
    Fengming Ji
    Chengchuang Wu
    Haoyu Tang
    Yucheng Xie
    Bing Yan
    Zhen Yang
    BMC Urology, 24